FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Clinical trials for FOCAL SEGMENTAL GLOMERULOSCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new FOCAL SEGMENTAL GLOMERULOSCLEROSIS trials appear
Sign up with your email to follow new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Common diabetes drug tested as new hope for scarring kidney disease
Disease control Recruiting nowThis study is testing if adding the drug metformin to standard care helps protect specialized kidney cells in people with FSGS, a disease that causes kidney scarring. Researchers want to see if metformin can reduce cell injury and slow disease progression over six months. The tri…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE1, PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug trial aims to protect transplanted kidneys from damage
Disease control Recruiting nowThis study is testing whether a medication called sparsentan can safely reduce protein in the urine of kidney transplant patients whose original kidney disease has returned. About 20 adult participants who received a transplant at least one year ago will take the daily tablet for…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE4 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New pill could slow kidney damage in devastating disease
Disease control Recruiting nowThis study is testing whether a new oral medicine called BI 764198 can help people with a serious kidney disease called focal segmental glomerulosclerosis (FSGS). About 286 adults and teenagers will take either the real medicine or a placebo pill daily for two years, while contin…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Race for new kidney disease treatments: three drugs enter human testing
Disease control Recruiting nowThis study is testing three new drugs (frexalimab, brivekimig, and rilzabrutinib) to see if they can help control two rare kidney diseases, FSGS and MCD. It will involve about 84 people aged 16-75 and will compare the drugs against a placebo over 24 weeks of treatment. The main g…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New oral treatment tested to slow scarring kidney disease
Disease control Recruiting nowThis study is testing if a nutritional supplement called ManNAc can help control a serious kidney disease called FSGS. It aims to see if taking ManNAc twice daily for 12 weeks safely reduces the amount of protein lost in urine, which is a key sign of kidney damage. The study will…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE2 • Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for kids with rare kidney diseases in 2-Year drug trial
Disease control Recruiting nowThis study is testing an oral medication called sparsentan in children aged 1 to 18 with specific rare kidney diseases. The main goal is to see if the drug is safe and can reduce harmful protein loss in urine over 108 weeks. Researchers will enroll about 67 children to monitor th…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
New hope for slowing scarring kidney disease
Disease control Recruiting nowThis study is testing whether an investigational drug called praliciguat can help control focal segmental glomerulosclerosis (FSGS), a disease that causes scarring in the kidneys. About 60 adults with confirmed FSGS will receive either the drug or a placebo for 24 weeks, followed…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE2 • Sponsor: Akebia Therapeutics • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
New system aims to connect kidney patients with right clinical trials
Knowledge-focused Recruiting nowThis study tests a new system that helps match kidney disease patients with clinical trials that might be right for them. It works by analyzing patient information to find trials targeting their specific type of kidney condition. The study also measures how well patients understa…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: NA • Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC